Entasis discovers and develops innovative antibacterials to fight diseases caused by multidrug-resistant bacteria. Our deep pipeline of innovative anti-infective programs is designed to revolutionize the way physicians treat serious bacterial infections. Our unique pathogen-targeted approach targets serious drug-resistant bacterial infections Entasis is a great place to work, combining the energy of biotech with the expertise and depth of global pharma.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.

News & Media
Our Pipeline

home-pipeline

With our unique approach, we are developing and advancing novel antibacterials to treat serious drug-resistant bacterial infections. Entasis’ robust pipeline consists of clinical and preclinical programs that target uncomplicated gonorrhea and serious Gram-negative infections including Pseudomonas aeruginosa, Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae.

Learn More
Join Us

home-join

At Entasis, our scientists and experts share a passion for innovation and collaboration. We are dedicated to research excellence and to pushing the boundaries of science to bring life-saving antibiotics to patients. Entasis is a great place to work and grow. We are currently recruiting for several key positions.

Learn More